The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study

Table 3

AUROC for Velacur™ assessments of LSM and attenuation parameters in different subject cohorts.

	Number of subjects	AUROC Velacur E (95% CI)	AUROC Velacur ACE (95% CI)
Healthy controls vs. patients	54 vs. 79	0.9379 (0.8805-0.9636)	0.9011 (0.8451-0.9454)
Healthy control vs. NAFLD patients	54 vs. 54	0.9156 (0.8617-0.9592)	0.9280 (0.8637-0.9636)
Healthy control vs. HCV SVR patients	54 vs. 25	0.9859 (0.9492-0.9969)	0.8430 (0.6831-0.9137)
Using  kPa and >8 kPa	62 vs. 71	0.9137 (0.8648-0.9564)	N/A
Using  dB/m and >238 dB/m	62 vs. 71	N/A	0.8458 (0.7753-0.9150)